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Abstract
Purpose: This study aimed to explore the associations between dose-volume parameters of local-
ized breast irradiation, longitudinal interleukin-6 soluble receptor (sIL-6R), and leukocyte counts
as markers of an immune-mediated response and fatigue as a centrally-driven behavior.
Methods and Materials: This prospective cohort study recruited 100 women who were diag-
nosed with stage 0-IIIa breast cancer, prescribed 40 Gy in 15 fractions over 3 weeks adjuvant
radiation therapy, and had no prior or concurrent chemotherapy. Dose-volume parameters were
derived from treatment plans and related to serum sIL-6R concentrations, leukocyte counts, and a
validated measure of self-reported fatigue at baseline, after 10 and 15 fractions, and 4 weeks after
radiation therapy.
Results: sIL-6R concertation was significantly higher in patients with a total volume of tissue ir-
radiated within the 50% isodose >2040 cm3 (P = .003). When controlling for body mass index, this
result only remained significant after treatment. The volume of liver irradiated within the 10% isodose
correlated with the sIL-6R concentration during and after radiation therapy (ρ = .3-.4; P = .03-
.007). The 38% of the cohort that was classified as fatigued had a higher mean sIL-6sR concentration
at all observation points, but the differences were only statistically significant during radiation therapy:
Mean (standard deviation [SD]) after 15 fractions for fatigued patients was 47.6 ng/dL (11.2 SD)
versus 41.6 ng/dL (11.4 SD) for nonfatigued patients (P = .01). Cohort leukocyte counts and leu-
kocyte subsets decreased consistently from baseline and the values for the fatigued group were 4%
lower at baseline and between 7% and 9% lower during and after treatment compared with those
of the nonfatigued group but the differences were not statistically significant.
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Conclusions: This is the first study to show that localized irradiation induces increased systemic
sIL-6R during treatment in participants who reported elevated levels of fatigue before, during, and
after treatment. This behavioral response appears to reflect a variation in innate host immunity, which
then mediates the cellular and/or psychological stress of radiation therapy.
© 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Fatigue is a recognizable defense against overexertion.
Cancer-related fatigue (CRF) also limits functioning but is
more intense and has an unpredictable relationship with ac-
tivity and rest.1 Such characteristics suggest why fatigue
is the predominant determinant of quality of life in women
who undergo radiation therapy for breast cancer.2 A key chal-
lenge to the effective management of radiation therapy-
related fatigue (RRF) is an understanding of its biological
basis.3 Objective radiobiological markers of fatigue would
help discriminate the component of RRF that is attribut-
able to the effects of radiation therapy from numerous
putative contributory factors.4
Therapeutic irradiation elicits a complex of inflamma-
tory responses that involve interstitial infiltration, clearance
of neutrophils, and consequential mononuclear cells and
inflammatory proteins.5 A principal mediator of this innate
immune response is the cytokine interleukin 6 (IL-6). Raised
levels of IL-6 have inconsistently been implicated in the
precipitation and potentiation of CRF.6 A limited range of
leukocytes and hepatocytes express the membrane-bound
receptor for IL-6 (mIL-6R).7 However, immunological stress
such as therapeutic irradiation readily induces the shed-
ding of mIL-6R to form an agonistic soluble receptor,
systemic interleukin-6 soluble receptor (sIL-6R).8 Shed sIL-
6R binds with high affinity to circulating IL-6 and enables
intracellular signaling via the transmembrane glycopro-
tein gp130. As gp130 is ubiquitously expressed by
parenchyma, stroma, endothelium, and nerves, almost uni-
versal systemic cell-signaling is enabled.
IL-6/sIL-6R trans-signaling establishes a theoretical link
between immune response within the localized radiation
portal and a centrally-perceived response such as fatigue.
Pathological control of IL-6 ultimately depends on sIL-
6R; therefore, RRF may be correlated with sIL-6R
concentration or the volumes of tissue that are irradiated.9
Increased irradiation of particular local structures have in-
consistently been linked with increased fatigue in patients
with breast10 and head and neck11 cancers.
The aim of this study is to explore the longitudinal re-
lationships between radiation dose-volume parameters,
leukocyte, and sIL-6R concentrations at an immunologi-
cal level as well as fatigue at the behavioral level. The
confounding effects of body mass index (BMI), anxiety,
and depression are also considered.
Methods and materials
A local research ethics committee (07/WSE04/82) ap-
proved this longitudinal cohort study. All participants
provided written informed consent.
Participants
Women who attended new patient clinics at the Velindre
Cancer Centre were consecutively invited to achieve a
sample size of 100. Eligible women were diagnosed with
stage group 0-IIIa carcinoma of the breast and prescribed
the UK adjuvant radiation therapy schedule of 40 Gy in 15
fractions over 3 weeks (±10 Gy/5 fractions boost). The prin-
cipal exclusion criteria were thyroid dysfunction;
inflammatory or autoimmune diseases; uncontrolled heart,
lung, or liver disease; history of significant or untreated de-
pression; prior or concurrent systemic endocrine or cytotoxic
therapy; and evidence of locally advanced or metastatic
disease. Prior systemic therapy was excluded to deter-
mine the pathophysiological effects of irradiation.
Observations
Sociodemographic, disease characteristic, and BMI data
were extracted from clinical case records. Psychological
mood was recorded using the hospital anxiety and depres-
sion scale.12 Baseline data were collected between 10 and
22 days before radiation therapy. Three longitudinal ob-
servations were timed to capture changes in the reported
course of RRF: after fraction 10, fraction 15, and 4 weeks
after the completion of radiation therapy. Participants were
asked to complete self-report questionnaires and provide
2 blood samples at each time point.
Fatigue measure
Fatigue intensity over the preceding 7 days was mea-
sured with the Functional Assessment of Chronic Illness
Therapy Fatigue Scale (FACIT-F), which is a 13-item ques-
tionnaire that generates a cumulative score between 0
(maximum fatigue) and 52 (no fatigue).13 Participants were
categorized as fatigued if the mean of their FACIT-F scores
at fractions 10 and 15 were ≤34.14
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Immunological measures
Differential leukocyte counts were auto-analyzed (Pentra
XL 80, Horiba ABX, Montpellier, France). The second blood
sample was centrifuged at 1500xg for 15 minutes and the
resultant sera stored at −70o C until analyzed. The con-
centration of sIL-6R was measured with enzyme-linked
immunosorbent assay kits (R&D Systems, Minneapolis,
MN).
Radiation therapy dose-volume parameters
A computed tomography planning scan with a 2-mm slice
thickness was conducted for all participants. Tangential fields
were optimized to create a nondivergent posterior border,
constrain the central lung distance to ≤20 mm, minimize
cardiac irradiation, and cover the planning target volume
(PTV) with 95% to 107% of the International Commis-
sion on Radiation Units and Measurements prescription point
dose.
The heart, liver, ipsilateral lung, and external outline were
delineated on an anonymous copy of the plan. The heart
was defined by the extent of the pericardial sac including
the roots of the great vessels and coronary arteries, and the
superior margin corresponded to the level of the left pul-
monary artery. The volume of tissue within the 95% isodose
was considered a proxy for the volume of the breast. An
experienced oncology radiologist reviewed the first 5 cases
prospectively to assess the reliability of structure delinea-
tion and a 5% random sample was selected retrospectively.
A collapsed cone convolution algorithm (Oncentra
MasterPlan v3.1) calculated the dose to the regions of in-
terest (ROIs). The minimum, maximum, and mean ROI
doses and the absolute and percentage volume of ROIs ir-
radiated to 10%, 50%, and 90% (ROI10, 50, 90, respectively)
of the prescription dose were recorded. If the full extent
of the liver was not included in the planning scan, only ab-
solute volumetric data (cm3) could be generated.
Data analysis
Independent t tests compared longitudinal measures
between the fatigued and nonfatigued groups. A linear fixed
model with repeated measures was used to determine the
impact of the overall PTV on sIL-6R concentration. Bi-
variate relationships between irradiation of individual organs
and sIL-6R were evaluated with Pearson’s correlations. Non-
parametric equivalents were used where data was not
normally distributed. Linear regression was used to inves-
tigate the association between irradiated volumes and sIL-
6R when controlling for patient and clinical variables.
Logistic regression was used to evaluate the odds of being
in the fatigued group on the basis of sIL-6R and clinical
variables. A significance level of P < .01 was adopted to
mitigate against multiple testing.
Results
The sociodemographic and clinical characteristics of the
100 participants have been described previously.14 Select
patient and disease characteristics are summarized in Table 1.
The course of the longitudinal measures for the fatigued
(n = 38) and nonfatigued (n = 62) groups are summarized
in Table 2. Independent sample t test comparisons were
made between the groups at each time point. Eighty-eight
patients had 4-week follow-up blood data because 12 women
declined to return for a blood test after treatment.
Association between irradiation and
interleukin-6 soluble receptor concentration
A linear model with repeated measures was conducted
to evaluate the association between PTV irradiation and
longitudinal sIL-6R development. Systemic sIL-6R
concentration was included at the 4 time points, and ordinal
Table 1 Summary of patient and disease-related characteristics
Patient characteristics
for sample (n = 100)
Fatigued
group
(n = 38)
Non-fatigued
group
(n = 62)
Mean (SD)
Age (years) 55.9 (9.3) 59.0 (8.5)
Body mass index (kg/m2) 29.2 (4.8) 27.6 (4.6)
Time from surgery to
radiation therapy (days)
61.5 (12.2) 61.0 (16.7)
Psychological mood
Anxiety 7.6 (4.8) 4.3 (2.8)
Depression 4.8 (3.4) 1.9 (2.0)
Total HADS score 6.2 (4.1) 12.3 (6.9)
Frequency n (%)
Menopausal status
Postmenopausal 25 (65) 48 (77.4)
Perimenopausal 7 (18.4) 9 (14.5)
Premenopausal 6 (15.8) 5 (8.1)
TNM stage
0 7 (18.4) 6 (9.7)
I 25 (65.8) 45 (72.6)
IIA 6 (15.8) 11 (17.7)
Laterality
Right 20 (52.6) 32 (51.6)
Left 18 (47.4) 30 (48.4)
Surgical procedure
Wide local excision 38 60
Mastectomy 0 2
Electron breast boost
10 Gy/5#/1 week
1 1
SCF irradiation
40 Gy/15#/3 weeks
1 2
HADS, Hospital Anxiety & Depression Scale; TNM stage, tumor, node,
metastases stage group; SCF, supra clavicular fossa; SD, standard
deviation.
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thirds categories of PTV50 (≤1359 cm3; 1360-2040;
>2040 cm3) were included as the between-subjects factor.
There was a large effect for time (F = 10.8; P < .001; partial
eta squared), which indicated a significant change in sIL-
6R concentrations across the 4 time points. The main effect
between the PTV groups was significant (F = 8.4; P < .001;
moderate partial eta effect size = 0.3).
Post hoc comparisons using Tukey’s honestly signifi-
cant difference test indicated that the greatest difference in
sIL-6R concentration was between the largest (>2040 cm3)
PTV50 group and the other two groups (P = .0003; Table 3).
Statistically comparable results were found for PTV10 and
PTV90.
The Pearson’s correlation between BMI and PTV50 was
ρ = .7. When BMI was included as a covariate in the model,
the effect for the PTV50 group was reduced to F = 3.9
(P = .24).
Correlations were performed between individual organ
10%, 50%, and 90% isodose values, mean organ dose, and
sIL-6R concentrations at all time points. The only statis-
tically significant result was between the liver subvolumes
and sIL-6R concentration for right-sided patients only (liver10
at time point 2: n = 52; ρ = .29; P = .03; time point 3: n = 52;
ρ = .33; P = .01; 4-week follow-up: n = 49; ρ = 0.40;
P = .007). After controlling for anxiety and depression, BMI,
age, tumor stage, and time from surgery to radiation therapy,
the volume of tissue within the 50% isodose remained sta-
tistically significant (beta = 0.43; P = .008). Overall, the
model explained 53% of the variance in sIL-6R concen-
tration at 4-weeks postradiation therapy.
Association between interleukin-6 soluble
receptor and fatigue
A series of independent samples t tests revealed signifi-
cant differences in the sIL-6R concentrations of the fatigued
and nonfatigued groups at weeks 2 and 3 of radiation therapy
but not pre- or post-treatment (Table 2). At week 3, fa-
tigued participants had significantly higher sIL-6R
concentrations (mean: 47.6 ng/dL [standard deviation:
11.2 ng/dL]) than nonfatigued participatns (mean: 41.6 ng/
dL [standard deviation: 11.4 ng/dL]; t = 2.48’; P = .01;
moderate eta squared effect size = 0.06).
Table 2 Longitudinal measures for the fatigued and nonfatigued groups before radiation therapy (time point 1), after fraction 10 (time
point 2), after fraction 15 (time point 3), and 4 weeks after completion of radiation therapy (time point 4)
Group Measure Mean (SD) Time point
1 2 3 4
(n = 88)
Nonfatigued
(n = 62)
FACIT-F 45.5 (6.4) 46.0 (5.1) 43.6 (6.7) 44.3 (7.4)
sIL-6R (ng/dL) 39.8 (11.3) 39.8 (10.7) 41.6 (11.4) 39.6 (12.2)
Leukocytes (x109/L) 7.0 (1.4) 6.5 (1.4) 6.0 (1.5) 5.8 (1.7)
Fatigued
(n = 38)
FACIT-F 33.9 (8.3)a 28.9 (8.0)a 23.1 (7.9)a 31.0 (10.9)a
sIL-6R (ng/dL) 43.5 (11.6) 44.8 (10.1)b 47.6 (11.2)c 41.5 (10.1)
Leukocytes (x109/L) 6.7 (1.6) 6.0 (1.6) 5.6 (1.7) 5.3 (1.4)
FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue scale; sIL-6R, soluble interleukin 6 receptor; SD, standard deviation.
a Significant at < .0005.
b Group difference significant at < .05.
c Significant at < .01.
Table 3 Fatigue scores and sIL-6R concentrations for ordinal thirds PTV50 categories
PTV50 group (cm3) Measure Mean (SD) Time point
1 2 3 4
(n = 88)
≤1359
(n = 34)
FACIT-F 43.3 (8.2) 41.7 (9.1) 38.7 (11.3) 42.9 (8.9)
sIL-6R (ng/dL) 36.2 (10.5) 38.4 (10.1) 39.6 (9.21) 35.1 (10.06)
1360-2040
(n = 33)
FACIT-F 40.8 (9.5) 38.6 (12.1) 34.3 (12.8) 37.5 (12.3)
sIL-6R (ng/dL) 41.1 (11.1) 41.6 (10.7) 42.9 (12.4) 39.4 (10.0)
>2040
(n = 33)
FACIT-F 38.9 (10.3) 38.3 (10.0) 34.3 (11.0) 37.3 (10.7)
sIL-6R (ng/dL) 47.0 (10.2)a 47.2 (11.4)a 50.7 (11.5)a 46.4 (11.4)a
FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue scale; PTV50, planning target volume irradiated within 50% isodose; sIL-6R,
soluble interleukin 6 receptor; SD, standard deviation.
a Significant at < 0.01.
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Association between irradiated volumes
and fatigue
The group with PTV50 <1359 cm3 remained the least
fatigued group during treatment (Table 3). FACIT-F scores
for the medium and large groups were almost identical
during and after radiation therapy. The volume of the lung
that was irradiated within the 10% and 50% isodose levels
and the maximum lung dose all correlated negatively with
FACIT-F score at week 3 and 4 weeks’ post-treatment
(ρ = 0.22-0.30; P = .01). At 4 weeks’ follow-up, the
maximum liver dose data revealed a small but statisti-
cally significant relationship with fatigue (ρ = 0.24; P = .01).
All correlations remained significant when controlling for
BMI.
Logistic regression was used to assess the likelihood of
being in the fatigued group based on age, anxiety and de-
pression, time from surgery to radiation therapy, tumor stage,
and volumes of irradiation and sIL-6R concentration during
radiation therapy. Only depression was a useful predictor
(odds ratio: 1.4; 95% confidence interval, 1.2-1.8; P = .03).
Discussion
The repeated measures data indicated that larger volumes
of irradiated thoracic tissue are associated with increased
peripheral sIL-6R concentrations. The moderate effect size
was comparable when considering the mean dose and volume
of tissue within the 10%, 50%, and 90% isodose, which
suggests that low dose effects are not a particular feature.
How much of the increase in sIL-6R can be attributed to
the direct effects of irradiation and how much is secondary
to positive associations between irradiated volumes and BMI
is complex because the latter 2 variables are strongly
correlated.11 Secondary associations with BMI (as a proxy
for adiposity) are likely to account for any relationship
between irradiated volumes and sIL-6R before radiation
therapy commences. Significant positive associations between
the volume of tissue irradiated within the primary beam and
sIL-6R were evident during treatment and at 4 weeks post-
treatment. Multivariable analysis suggests that the increase
in sIL-6R relates to a larger treated volume.
There were no statistically significant associations
between cardiac or pulmonary dose-volumetric param-
eters and sIL-6R concentration at any time point.
Correlations between the volume of liver that was irradi-
ated within the 10% isodose and sIL-6R concentration were
statistically nonsignificant before radiation therapy but con-
sistently significant during and after for participants with
right-sided tumors. Medium-strength associations suggest
that the irradiation of a sufficiently large volume of liver
is associated with a peripherally detectable increase in sIL-
6R concentration (hepatocytes are a main source of systemic
sIL-6R).15 No correlations existed for left-sided tumors,
which supports the hypothesis that radiation dose to the liver
was a substantive effect rather than a consequence of in-
creased BMI. However, a higher BMI was clearly associated
with both larger volumes of hepatic irradiation (for right-
sided disease) and elevated peripheral sIL-6R.
The overall pattern of data supports the hypothesis of
a probable causal link between targeted radiation and serum
sIL-6R concentration. However, there was considerable het-
erogeneity within the sIL-6R data. The active role of the
host immune system in mediating individual response to
localized radiation therapy is a developing area, with par-
ticular focus on the so-called abscopal anti-tumor effects
on distant systemic disease.16,17 The idea that standard dose-
volume parameters determine local tissue response but the
host immune system mediates systemic effects has rel-
evance for sensitivity to fatigue with a minority of patients
suffering disproportionately. Therefore, the next consider-
ation was whether sIL-6R concentration or volumes of
irradiation related to fatigue at the behavioral level.
Relationship between interleukin-6 soluble
receptor and fatigue
Before radiation therapy, there was no significant dif-
ference in sIL-6R concentrations between the fatigued and
nonfatigued groups. By week 3 of radiation therapy, sIL-
6R was significantly elevated within the fatigued but not
in the nonfatigued group. Considering the extremes of
fatigue, a subgroup of participants with fatigue scores below
the bottom quintile recorded virtually no change in con-
centration (37.1-37.0 ng/mL) from baseline to week 3
compared with the most fatigued fifth (41.9-51.3 ng/mL).
Both findings are consistent with the concept of a sub-
group of participants who are defined by preexisting factors
that are susceptible to an exaggerated inflammatory re-
sponse during radiation therapy.
To our knowledge this is the first time sIL-6R has been
related to acute fatigue toxicity and extends the limited data
linking sIL-6R and chronic fatigue after treatment for breast
cancer.9 A noteworthy trend is that total leukocyte counts
and all leukocyte subsets except basophils were lower in
the fatigued group at baseline (–4.4%) and all subsequent
points (–7% to −9%) compared with the nonfatigued group.
This differential did not reach statistical significance, pre-
ceded radiation therapy, and is consistent with previously
demonstrated innate immunological characteristics of CRF
in survivors of breast cancer.9 Increased cytokine expres-
sion and fatigue have also been linked with more severe
skin reactions due to breast radiation therapy, which suggests
a potential external indicator of inherited susceptibility.18,19
Volumes of irradiated tissue as a predictor
of fatigue
This study extends the limited data that evaluate the link
between radiation dose-volume parameters and increased
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fatigue.10,11 When controlling for psychological mood, the
absolute volume of thoracic tissue that is irradiated by the
primary beam was not a useful predictor of fatigue in women
with breast cancer, which uniquely explains approxi-
mately 1% of the variance14
The group with the smallest volume irradiated were the
least fatigued before, during, and after treatment. This re-
lationship may be evident due to links between lower BMI
and greater physical activity and improved psychological
mood. However, a report that stated that patients under-
going partial breast radiation therapy experienced less fatigue
and improved quality of life compared with whole breast
radiation therapy10 suggests that standard radiobiological
principles and toxicity probability increase with volume of
normal tissues irradiated and has clinical relevance for RRF.
The local recurrence risk-stratification approach that was
tested in the IMPORT low trial20 provides a partial breast
planning approach with the potential to minimize RRF as
well as other early and late treatment toxicity. More broadly,
unanticipated fatigue toxicity that is associated with low
dose effects should be considered21 as the use of intensity
modulated radiation therapy expands.
When considering individual organs, no significant as-
sociations were evident between any cardiac dose-volumetric
parameter and fatigue. Cardiac irradiation does not appear
to contribute to either sIL-6R concentration or fatigue during
the acute period. The study findings were in accordance with
an abstract presented at an American Society of Clinical
Oncology conference that found no relationship between
cardiac irradiated volumes and fatigue in 48 patients with
early breast cancer.22 The abstract did report significant cor-
relations between the volume of lung irradiated and fatigue.
In the current study, the volume of lung that was irra-
diated within the 10% and 50% isodose levels and the
maximum lung dose all correlated negatively with FACIT-F
score at week 3 and 4 weeks posttreatment, which sug-
gests a small-to-moderate association between larger
volumes of lung irradiated and increased fatigue. These cor-
relations remained significant when BMI was controlled
for.
Finally, at 4-week follow-up, the maximum liver dose
data revealed a small but statistically significant relation-
ship fatigue (ρ = 0.24; P = .01). Hepatocytes are one of the
few cells (other than leukocytes) to express the mem-
brane bound IL-6 receptor. As the liver plays a central role
in metabolizing cytotoxic agents, the clinical relevance of
these finding may be increased when considering the sched-
uling of chemotherapy and radiation therapy treatments. In
summary, lung and liver irradiation may contribute to the
pathophysiology of RRF.
As the single largest study of its type, these results are
a reliable basis for hypothesis generation. However, the mul-
tiple comparisons that were performed may yield statistically
significant results with little or no clinical significance. A
reduced significance level partially addressed this limita-
tion. The use of a single cytokine and reliance on cross-
sectional correlations may not reflect the wave-like release
of cytokines in response to radiation.5 Finally, the results
should be applied with caution to patients who received prior
chemotherapy.
Conclusions
The current study revealed an acute elevation in sIL-
6R as a response to irradiation, which is of greater magnitude
in more fatigued participants. These results were not con-
founded by the effects of chemotherapy. The respective
courses of fatigue, sIL-6R, and leukocytes suggest that ra-
diation therapy exacerbates a premorbid immunological state
in fatigued participants. Susceptibility to debilitating sys-
temic effects, such as fatigue via IL-6/sIL-6R regulated
signaling, suggests a promising therapeutic target in addi-
tion to psychological and behavioral support. Larger BMI
and/or breast size may be a useful external indicator of
higher-risk patients.
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